<DOC>
	<DOCNO>NCT00016887</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill cancer cell . Peripheral stem cell transplant may allow doctor give high dos chemotherapy drug kill cancer cell . Interferon alfa may interfere growth cancer cell . It yet know whether give one drug ( combination chemotherapy ) radiation therapy peripheral stem cell transplant effective chemotherapy follow interferon alfa treat mantle cell lymphoma . PURPOSE : This randomized phase III trial compare well chemotherapy follow radiation therapy , chemotherapy , peripheral stem cell transplant work compare chemotherapy plus interferon alfa treat patient stage III stage IV mantle cell lymphoma .</brief_summary>
	<brief_title>Chemotherapy Followed Radiation Therapy Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa Treating Patients With Stage III Stage IV Mantle Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare disease-free survival patient previously untreated advanced mantle cell lymphoma treat intensified chemotherapy follow myeloablative radiochemotherapy peripheral blood stem cell transplantation ( PBSCT ) v standard therapy interferon alfa maintenance . - Compare overall survival patient treat early v late myeloablative radiochemotherapy PBSCT . - Compare disease-free survival overall survival patient treat regimen v historic control similar case . OUTLINE : This randomize , multicenter study . Patients stratify accord risk factor ( ECOG performance status great 1 , LDH serum level normal , and/or extranodal lymphoma involvement ) participate center . Patients randomize 1 2 treatment arm . - Induction : All patient receive 4 course cytoreductive chemotherapy comprise anthracycline-containing combination . Patients achieve complete remission 4 course receive 2 additional course induction chemotherapy . Patients without least partial response 6 course discontinue treatment ; least partial response proceed arm I II . Arm I - Consolidation : Patients achieve complete partial remission 4-6 course induction therapy begin intensify chemotherapy within 6 week . Patients receive oral dexamethasone daily day 1-10 , carmustine IV day 2 , melphalan IV day 3 , etoposide IV daily cytarabine IV twice day day 4-7 . Patients also receive filgrastim ( G-CSF ) begin day 11 continue peripheral blood stem cell ( PBSC ) harvest . - Within 4-6 week PBSC harvest , patient undergo myeloablative radiochemotherapy comprise radiotherapy day -6 -4 cyclophosphamide IV day -3 -2 . Patients undergo PBSC transplantation day 0 . Arm II - Consolidation : Patients receive 2 additional course induction chemotherapy consolidation ( total 8 chemotherapy course ) . - Maintenance : Within 4 week arm II consolidation , patient receive interferon alfa subcutaneously ( SC ) 3 day week absence unacceptable toxicity disease progression relapse . Patients experience first relapse progression maintenance therapy may receive intensified chemotherapy arm I . Patients follow every 3 month . PROJECTED ACCRUAL : A total 210 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage III IV mantle cell lymphoma Previously untreated Not qualified primary potentially curative radiotherapy PATIENT CHARACTERISTICS : Age : 18 65 year Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : No impairment liver function ( unless due lymphoma ) Transaminases great 3 time normal Bilirubin great 2.0 mg/dL Renal : No renal insufficiency Creatinine great 2.0 mg/dL Cardiovascular : No manifest heart failure coronary heart disease No severe uncontrolled hypertension Pulmonary : No chronic lung disease hypoxemia Other : Not pregnant nursing Fertile patient must use effective contraception No severe uncontrolled diabetes mellitus PRIOR CONCURRENT THERAPY : Biologic therapy : No prior interferon No prior organ , bone marrow , peripheral blood stem cell transplantation Chemotherapy : No prior cytostatic chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2003</verification_date>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
</DOC>